Small molecules affecting transcription in Friedreich ataxia

Pharmacology and Therapeutics

Volumn 116, Issue 2, 2007, Pages 236-248

  Gottesfeld, Joel M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Frataxin; Friedreich ataxia; Histone deacetylase inhibitor; Polyamides; Transcription

Indexed keywords

3 NITROPROPIONIC ACID; 4',6 DIAMIDINO 2 PHENYLINDOLE; ANTIOXIDANT; BIGUANIDE; BUTYRIC ACID; CISPLATIN; DIMINAZENE; DISTAMYCIN A; FRATAXIN; GUANIDINE DERIVATIVE; HEMIN; HETEROCHROMATIN PROTEIN 1; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRON CHELATING AGENT; MANGANESE SUPEROXIDE DISMUTASE; PENTAMIDINE; POLYAMIDE; RECOMBINANT ERYTHROPOIETIN; SECRETED FRIZZLED RELATED PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; AMINO ACID SEQUENCE; CANCER CELL CULTURE; CARDIOMYOPATHY; CHROMATIN CONDENSATION; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; COLON CARCINOMA; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA BINDING; DNA METHYLATION; DNA MICROARRAY; DNA STRUCTURE; DRUG INHIBITION; FRIEDREICH ATAXIA; FXN GENE; GENE; GENE ACTIVATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENE THERAPY; GENETIC TRANSCRIPTION; HEART DISEASE; HUMAN; INTRON; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; SCOLIOSIS; TRANSCRIPTION INITIATION;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HUMANS; IRON-BINDING PROTEINS; MICE; MUTATION; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 34748841015     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2007.06.014     Document Type: Review

References (83)

1. Al-Mahdawi S., Pinto R.M., Varshney D., Lawrence L., Lowrie M.B., Hughes S., et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88 (2006) 580-590
2. Annunziato A.T., and Hansen J.C. Role of histone acetylation in the assembly and modulation of chromatin structures. Gene Expr 9 (2000) 37-61
3. Annunziato A.T., Frado L.L., Seale R.L., and Woodcock C.L. Treatment with sodium butyrate inhibits the complete condensation of interphase chromatin. Chromosoma 96 (1988) 132-138
4. Babcock M., de Silva D., Oaks R., Davis-Kaplan S., Jiralerspong S., Montermini L., et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276 (1997) 1709-1712
5. Bencze K.Z., Kondapalli K.C., Cook J.D., McMahon S., Millan-Pacheco C., Pastor N., et al. The structure and function of frataxin. Crit Rev Biochem Mol Biol 41 (2006) 269-291
6. Bernstein E., and Allis C.D. RNA meets chromatin. Genes Dev 19 (2005) 1635-1655
7. Bidichandani S.I., Ashizawa T., and Patel P.I. Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion. Am J Hum Genet 60 (1997) 1251-1256
8. Bidichandani S.I., Ashizawa T., and Patel P.I. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 62 (1998) 111-121
9. Blattes R., Monod C., Susbielle G., Cuvier O., Wu J.H., Hsieh T.S., et al. Displacement of D1, HP1 and topoisomerase II from satellite heterochromatin by a specific polyamide. EMBO J 25 (2006) 2397-2408
10. Boddaert N., Le Quan Sang K.H., Rotig A., Leroy-Willig A., Gallet S., Brunelle F., et al. Selective iron chelation in Friedreich ataxia. Biological and clinical implications. Blood Selective Iron Chelation in Friedreich Ataxia. Biological and Clinical Implications (2007)
11. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97 (2000) 10526-10531
12. Bulteau A.L., O'Neill H.A., Kennedy M.C., Ikeda-Saito M., Isaya G., and Szweda L.I. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305 (2004) 242-245
13. Burnett R., Melander C., Puckett J.W., Son L.S., Wells R.D., Dervan P.B., et al. DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia. Proc Natl Acad Sci U S A 103 (2006) 11497-11502
14. Calabrese V., Lodi R., Tonon C., D'Agata V., Sapienza M., Scapagnini G., et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci 233 (2005) 145-162
15. Campuzano V., Montermini L., Molto M.D., Pianese L., Cossee M., Cavalcanti F., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
16. Chaires J.B. Competition dialysis: an assay to measure the structural selectivity of drug-nucleic acid interactions. Curr Med Chem Anticancer Agents 5 (2005) 339-352
17. Cho D.H., Thienes C.P., Mahoney S.E., Analau E., Filippova G.N., and Tapscott S.J. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell 20 (2005) 483-489
18. Clark R.M., De Biase I., Malykhina A.P., Al-Mahdawi S., Pook M., and Bidichandani S.I. The GAA triplet-repeat is unstable in the context of the human FXN locus and displays age-dependent expansions in cerebellum and DRG in a transgenic mouse model. Hum Genet (2006)
19. Dervan P.B. Molecular recognition of DNA by small molecules. Bioorg Med Chem 9 (2001) 2215-2235
20. Dervan P.B., and Edelson B.S. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol 13 (2003) 284-299
21. Di Prospero N.A., and Fischbeck K.H. Therapeutics development for triplet repeat expansion diseases. Nat Rev Genet 6 (2005) 756-765
22. El-Osta A., and Wolffe A.P. DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. Gene Expr 9 (2000) 63-75
23. Elgin S.C., and Grewal S.I. Heterochromatin: silence is golden. Curr Biol 13 (2003) R895-R898
24. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23 (2003) 9418-9427
25. Festenstein R. Breaking the silence in Friedreich's ataxia. Nat Chem Biol 2 (2006) 512-513
26. Galvin K.A., and Jones D.G. Adult human neural stem cells for autologous cell replacement therapies for neurodegenerative disorders. NeuroRehabilitation 21 (2006) 255-265
27. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280 (2005) 556-563
28. Ghazizadeh M. Cisplatin may induce frataxin expression. J Nippon Med Sch 70 (2003) 367-371
29. Gomez-Sebastian S., Gimenez-Cassina A., Diaz-Nido J., Lim F., and Wade-Martins R. Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia deficiency in human cells. Mol Ther 15 (2007) 248-254
30. Gottesfeld J.M., Turner J.M., and Dervan P.B. Chemical approaches to control gene expression. Gene Expr 9 (2000) 77-91
31. Grabczyk E., and Usdin K. Alleviating transcript insufficiency caused by Friedreich's ataxia triplet repeats. Nucleic Acids Res 28 (2000) 4930-4937
32. *TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res 28 (2000) 2815-2822
33. Grant L., Sun J., Xu H., Subramony S.H., Chaires J.B., and Herbert M.D. Rational selection of small molecules that increase transcription through the GAA repeats found in Friedreich's ataxia. FEBS Lett 580 (2006) 5399-5405
34. Greene E., Entezam A., Kumari D., and Usdin K. Ancient repeated DNA elements and the regulation of the human frataxin promoter. Genomics 85 (2005) 221-230
35. Greene E., Mahishi L., Entezam A., Kumari D., and K. U. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res 35 (2007) 3383-3390
36. Harding A.E. Clinical features and classification of inherited ataxias. Adv Neurol 61 (1993) 1-14
37. Hart P.E., Lodi R., Rajagopalan B., Bradley J.L., Crilley J.G., Turner C., et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 62 (2005) 621-626
38. Herman D., Jenssen K., Burnett R., Soragni E., Perlman S.L., and Gottesfeld J.M. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2 (2006) 551-558
39. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100 (2003) 2041-2046
40. Huang Y., Greene E., Murray Stewart T., Goodwin A.C., Baylin S.B., Woster P.M., et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A 104 (2007) 8023-8028
41. Janssen S., Cuvier O., Müller M., and Laemmli U.K. Specific gain- and loss-of-function phenotypes induced by satellite-specific DNA-binding drugs fed to Drosophila melanogaster. Mol Cell 6 (2000) 1013-1024
42. Janssen S., Durussel T., and Laemmli U.K. Chromatin opening of DNA satellites by targeted sequence-specific drugs. Mol Cell 6 (2000) 999-1011
43. Kernochan L.E., Russo M.L., Woodling N.S., Huynh T.N., Avila A.M., Fischbeck K.H., et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet 14 (2005) 1171-1182
44. *(TTC)n repeats on RNA synthesis and stability. Nucleic Acids Res 35 (2007) 1075-1084
45. Langley B., Gensert J.M., Beal M.F., and Ratan R.R. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord 4 (2005) 41-50
46. Lodi R., Tonon C., Calabrese V., and Schapira A.H. Friedreich's ataxia: from disease mechanisms to therapeutic interventions. Antioxid Redox Signal 8 (2006) 438-443
47. Mackenzie J.A., and Payne R.M. Mitochondrial protein import and human health and disease. Biochim Biophys Acta 1772 (2007) 509-523
48. Mariappan S.V., Catasti P., Silks III L.A., Bradbury E.M., and Gupta G. The high-resolution structure of the triplex formed by the GAA/TTC triplet repeat associated with Friedreich's ataxia. J Mol Biol 285 (1999) 2035-2052
49. Mateescu B., England P., Halgand F., Yaniv M., and Muchardt C. Tethering of HP1 proteins to chromatin is relieved by phosphoacetylation of histone H3. EMBO Rep 5 (2004) 490-496
50. Maueler W., Bassili G., Epplen C., Keyl H.G., and Epplen J.T. Protein binding to simple repetitive sequences depends on DNA secondary structure(s). Chromosome Res 7 (1999) 163-166
51. Miranda C.J., Santos M.M., Ohshima K., Smith J., Li L., Bunting M., et al. Frataxin knockin mouse. FEBS Lett 512 (2002) 291-297
52. Napierala M., Dere R., Vetcher A., and Wells R.D. Structure-dependent recombination hot spot activity of GAA.TTC sequences from intron 1 of the Friedreich's ataxia gene. J Biol Chem 279 (2004) 6444-6454
53. Ohshima K., Montermini L., Wells R.D., and Pandolfo M. Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem 273 (1998) 14588-14595
54. Oktay Y., Dioum E., Matsuzaki S., Ding K., Yan L.J., Haller R.G., et al. Hypoxia-inducible factor 2alpha regulates expression of the mitochondrial aconitase chaperone protein frataxin. J Biol Chem 282 (2007) 11750-11756
55. Pandolfo M. Friedreich's ataxia: clinical aspects and pathogenesis. Semin Neurol 19 (1999) 311-321
56. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102 (2005) 3697-3702
57. Pianese L., Turano M., Lo Casale M.S., De Biase I., Giacchetti M., Monticelli A., et al. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry 75 (2004) 1061-1063
58. Puccio H. Conditional mouse models for Friedreich ataxia, a neurodegenerative disorder associating cardiomyopathy. Handb Exp Pharmacol 178 (2007) 365-375
59. Puccio H., Simon D., Cossee M., Criqui-Filipe P., Tiziano F., Melki J., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27 (2001) 181-186
60. Richardson D.R. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opin Investig Drugs 12 (2003) 235-245
61. Riessland M., Brichta L., Hahnen E., and Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 120 (2006) 101-110
62. Rotig A., Sidi D., Munnich A., and Rustin P. Molecular insights into Friedreich's ataxia and antioxidant-based therapies. Trends Mol Med 8 (2002) 221-224
63. Sakamoto N., Chastain P.D., Parniewski P., Ohshima K., Pandolfo M., Griffith J.D., et al. Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia. Mol Cell 3 (1999) 465-475
64. *TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem 276 (2001) 27171-27177
65. Sarsero J.P., Li L., Wardan H., Sitte K., Williamson R., and Ioannou P.A. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J Gene Med 5 (2003) 72-81
66. Sarsero J.P., Holloway T.P., Li L., McLenachan S., Fowler K.J., Bertoncello I., et al. Evaluation of an FRDA-EGFP genomic reporter assay in transgenic mice. Mamm Genome 16 (2005) 228-241
67. Saveliev A., Everett C., Sharpe T., Webster Z., and Festenstein R. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422 (2003) 909-913
68. Seznec H., Simon D., Monassier L., Criqui-Filipe P., Gansmuller A., Rustin P., et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 13 (2004) 1017-1024
69. Seznec H., Simon D., Bouton C., Reutenauer L., Hertzog A., Golik P., et al. Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet 14 (2005) 463-474
70. Shogren-Knaak M., Ishii H., Sun J.M., Pazin M.J., Davie J.R., and Peterson C.L. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311 (2006) 844-847
71. Shults C.W., and Haas A.E. Clinical trials of coenzyme Q10 in neurological disorders. Biofactors 25 (2005) 117-126
72. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
73. Sturm B., Stupphann D., Kaun C., Boesch S., Schranzhofer M., Wojta J., et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest 35 (2005) 711-717
74. Tapscott S.J., Klesert T.R., Widrow R.J., Stoger R., and Laird C.D. Fragile-X syndrome and myotonic dystrophy: parallels and paradoxes. Curr Opin Genet Dev 8 (1998) 245-253
75. Trauger J.W., Baird E.E., and Dervan P.B. Subnanomolar sequence-specific recognition in the minor groove of DNA by designed ligands. Nature (London) 382 (1996) 559-561
76. Tse C., Sera T., Wolffe A.P., and Hansen J.C. Disruption of higher-order folding by core histone acetylation dramatically enhances transcription of nucleosomal arrays by RNA polymerase III. Mol Cell Biol 18 (1998) 4629-4638
77. Turano M., Tammaro A., De Biase I., Lo Casale M.S., Ruggiero G., Monticelli A., et al. 3-Nitropropionic acid increases frataxin expression in human lymphoblasts and in transgenic rat PC12 cells. Neurosci Lett 350 (2003) 184-186
78. Urbach A.R., and Dervan P.B. Toward rules for 1:1 polyamide:DNA recognition. Proc Natl Acad Sci U S A 98 (2001) 4343-4348
79. Urbach A.R., Love J.J., Ross S.A., and Dervan P.B. Structure of a beta-alanine-linked polyamide bound to a full helical turn of purine tract DNA in the 1:1 motif. J Mol Biol 320 (2002) 55-71
80. Wemmer D.E., and Dervan P.B. Targeting the minor groove of DNA. Curr Opin Struct Biol 7 (1997) 355-361
81. Whittom, A. A., Ragazzon, P. A., Subramony, S. H., Boykin, D. W., Chaires, J. B. & Hebert, M. D. (submitted for publication). Aromatic amidines increase transcription through FAA repeats found in Friedreich ataxia.
82. Wong J.C., Hong R., and Schreiber S.L. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc 125 (2003) 5586-5587
83. Xenocostas A., Cheung W.K., Farrell F., Zakszewski C., Kelley M., Lutynski A., et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 61 (2005) 189-195